4.8 Article

Microengineered Multi-Organoid System from hiPSCs to Recapitulate Human Liver-Islet Axis in Normal and Type 2 Diabetes

Journal

ADVANCED SCIENCE
Volume 9, Issue 5, Pages -

Publisher

WILEY
DOI: 10.1002/advs.202103495

Keywords

hiPSCs; liver; multi-organoid-on-chip; pancreatic islet

Funding

  1. Strategic Priority Research Program of the Chinese Academy of Sciences [XDA16020900, XDB29050301, XDB32030200]
  2. National Key R&D Program of China [2017YFB0405404]
  3. Yunnan Key Research and Development Program [202003AD150009]
  4. National Nature Science Foundation of China [31971373]
  5. DICP, CAS [DICP I201934]

Ask authors/readers for more resources

A new microfluidic multi-organoid system has been developed to replicate the human liver-pancreatic islet axis in both normal and disease states, providing a unique platform for future research and drug development in Type 2 diabetes mellitus.
Type 2 diabetes mellitus (T2DM) is a systematic multi-organ metabolic disease, which is characterized by the dynamic interplay among different organs. The increasing incidence of T2DM reflects an urgent need for the development of in vitro human-relevant models for disease study and drug therapy. Here, a new microfluidic multi-organoid system is developed that recapitulates the human liver-pancreatic islet axis in normal and disease states. The system contains two compartmentalized regions connected by a microchannel network, enabling 3D co-culture of human induced pluripotent stem cells (hiPSC)-derived liver and islet organoids for up to 30 days under circulatory perfusion conditions. The co-cultured liver and islet organoids exhibit favorable growth and improved tissue-specific functions. Transcriptional analyses reveal the activation of metabolically relevant signaling pathways in the co-cultured organoids. Notably, the co-culture system facilitates sensitive glucose-stimulated insulin secretion from islet organoids and increased glucose utilization in liver organoids by glucose tolerance tests. Both liver and islet organoids display mitochondrial dysfunction and decreased glucose transport capacity under high glucose conditions, which can be alleviated by metformin treatment. This novel multi-organoid system can recapitulate human-relevant liver-islet axis under both physiological and pathological conditions, providing a unique platform for future T2DM research and drug development.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available